HAE – Haemonetics Corporation
HAE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
6.76
Margin Of Safety %
-9
Put/Call OI Ratio
0.35
EPS Next Q Diff
-0.01
EPS Last/This Y
3.16
EPS This/Next Y
0.54
Price
75.12
Target Price
85.2
Analyst Recom
1.73
Performance Q
39.01
Upside
-40.5%
Beta
0.49
Ticker: HAE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-06-02 | HAE | 66.36 | 0.20 | 0.20 | 3698 |
| 2026-06-03 | HAE | 65.88 | 0.20 | 0.00 | 3703 |
| 2026-06-04 | HAE | 69.86 | 0.20 | 0.08 | 3715 |
| 2026-06-05 | HAE | 71.29 | 0.19 | 0.02 | 3770 |
| 2026-06-08 | HAE | 74.9 | 0.19 | 0.00 | 3829 |
| 2026-06-09 | HAE | 78.81 | 0.19 | 0.07 | 3920 |
| 2026-06-10 | HAE | 78.78 | 0.16 | 0.10 | 4491 |
| 2026-06-11 | HAE | 79.9 | 0.16 | 0.42 | 4591 |
| 2026-06-12 | HAE | 78.18 | 0.26 | 1.60 | 7924 |
| 2026-06-15 | HAE | 76.92 | 0.26 | 0.81 | 7928 |
| 2026-06-16 | HAE | 74.48 | 0.26 | 2.75 | 7927 |
| 2026-06-17 | HAE | 72.83 | 0.26 | 1.00 | 7934 |
| 2026-06-18 | HAE | 74.19 | 0.26 | 0.25 | 7935 |
| 2026-06-22 | HAE | 72.53 | 0.35 | 0.07 | 5242 |
| 2026-06-23 | HAE | 72.78 | 0.35 | 4.25 | 5260 |
| 2026-06-24 | HAE | 72.86 | 0.35 | 0.18 | 5262 |
| 2026-06-25 | HAE | 77.68 | 0.35 | 0.09 | 5303 |
| 2026-06-26 | HAE | 77.39 | 0.35 | 0.50 | 5324 |
| 2026-06-29 | HAE | 75.12 | 0.35 | 0.01 | 5328 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-06-01 | HAE | 67.24 | 0.2 | 109.9 | 5.22 |
| 2026-06-02 | HAE | 66.35 | 0.2 | 108.9 | 5.22 |
| 2026-06-03 | HAE | 65.85 | 0.2 | 110.0 | 5.22 |
| 2026-06-04 | HAE | 69.89 | 0.2 | 124.0 | 5.22 |
| 2026-06-05 | HAE | 71.33 | 0.2 | 115.9 | 5.22 |
| 2026-06-08 | HAE | 74.89 | 0.2 | 122.0 | 5.22 |
| 2026-06-09 | HAE | 78.70 | 0.2 | 122.2 | 5.22 |
| 2026-06-10 | HAE | 78.80 | 0.2 | 111.9 | 5.22 |
| 2026-06-11 | HAE | 80.11 | 0.2 | 115.1 | 5.22 |
| 2026-06-12 | HAE | 78.20 | 0.2 | 107.3 | 5.22 |
| 2026-06-15 | HAE | 76.95 | 0.2 | 108.2 | 5.22 |
| 2026-06-16 | HAE | 74.42 | -1.2 | 104.8 | 5.22 |
| 2026-06-17 | HAE | 72.82 | -1.2 | 107.1 | 5.22 |
| 2026-06-18 | HAE | 74.16 | -1.2 | 115.7 | 5.22 |
| 2026-06-22 | HAE | 72.56 | -1.2 | 107.1 | 5.22 |
| 2026-06-23 | HAE | 72.78 | -1.2 | 112.3 | 5.22 |
| 2026-06-24 | HAE | 72.86 | -1.2 | 111.8 | 5.22 |
| 2026-06-25 | HAE | 77.63 | -1.2 | 125.1 | 5.22 |
| 2026-06-26 | HAE | 77.32 | -1.2 | 110.8 | 5.22 |
| 2026-06-29 | HAE | 75.12 | -1.2 | 105.7 | 5.22 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-06-02 | HAE | 0.00 | -7.22 | 5.79 |
| 2026-06-03 | HAE | 0.00 | -7.22 | 5.79 |
| 2026-06-04 | HAE | 0.00 | -7.22 | 5.79 |
| 2026-06-05 | HAE | 0.00 | -7.22 | 5.79 |
| 2026-06-08 | HAE | 0.00 | -7.19 | 5.79 |
| 2026-06-09 | HAE | 0.00 | -7.19 | 5.79 |
| 2026-06-10 | HAE | 0.00 | -7.19 | 6.63 |
| 2026-06-11 | HAE | 0.00 | -7.19 | 6.63 |
| 2026-06-12 | HAE | 0.00 | -7.19 | 6.63 |
| 2026-06-15 | HAE | 0.00 | -6.89 | 6.63 |
| 2026-06-16 | HAE | 0.00 | -6.89 | 6.63 |
| 2026-06-17 | HAE | 0.00 | -6.89 | 6.63 |
| 2026-06-18 | HAE | 0.00 | -6.89 | 6.63 |
| 2026-06-22 | HAE | 0.00 | -6.87 | 6.65 |
| 2026-06-23 | HAE | 0.00 | -6.87 | 6.65 |
| 2026-06-24 | HAE | 0.00 | -6.87 | 6.65 |
| 2026-06-25 | HAE | 0.00 | -6.87 | 6.65 |
| 2026-06-26 | HAE | 0.00 | -6.87 | 6.78 |
| 2026-06-29 | HAE | 0.00 | -6.87 | 6.76 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.29
Avg. EPS Est. Current Quarter
1.09
Avg. EPS Est. Next Quarter
1.28
Insider Transactions
Institutional Transactions
-6.87
Beta
0.49
Average Sales Estimate Current Quarter
328
Average Sales Estimate Next Quarter
342
Fair Value
68.02
Quality Score
71
Growth Score
74
Sentiment Score
75
Actual DrawDown %
23.3
Max Drawdown 5-Year %
-51
Target Price
85.2
P/E
36.97
Forward P/E
13.04
PEG
1.62
P/S
2.56
P/B
4.27
P/Free Cash Flow
13.11
EPS
2.03
Average EPS Est. Cur. Y
5.22
EPS Next Y. (Est.)
5.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
7.29
Relative Volume
0.69
Return on Equity vs Sector %
-15.4
Return on Equity vs Industry %
0.4
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
105.7
◆
HAE
Healthcare
$75.12
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
59
Range 1M
63.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5.2%
EPS NY
10.4%
52W%
71.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+34.2% upside
Upside
+34.2%
Quality
71
MoS
-9%
HAE — P/E HistoricalMedical Instruments & Supplies
Haemonetics CorporationSector: Healthcare
Industry: Medical Devices
Employees: 3009
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE
Latest News
—
Caricamento notizie per HAE…
stock quote shares HAE – Haemonetics Corporation Stock Price stock today
news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch HAE – Haemonetics Corporation yahoo finance google finance
stock history HAE – Haemonetics Corporation invest stock market
stock prices HAE premarket after hours
ticker HAE fair value insiders trading